A new study is generating critical evidence to guide the optimal management of HIV patients who are failing treatment and developing resistance to the drug dolutegravir, offering hope to millions of HIV-positive individuals across Africa and worldwide.
HIV is treated through antiretroviral drugs that suppress the virus in the body, allowing people living with HIV to live long, healthy lives and prevent transmission. Today, most treatment regimens in Africa, including Kenya and around the world contain a drug called dolutegravir (DTG), which is the most important component of that treatment. When treatment is taken consistently, the amount of virus in the blood (viral load) drops to very low levels, protecting the immune system and preventing serious infections. However, people may experience treatment failure if they do not adhere to treatment, causing the viral load to rise. In some cases, the virus can also develop resistance to treatment, meaning the medicines no longer work effectively. Failure while on dolutegravir is concerning, as there are limited options available for treatment, putting people at risk of death.
